POS1054 FREQUENCY AND MODALITIES OF SCREENING FOR ILD: A SURVEY OF 1132 PATIENTS WITH RA
Authors: A. M. Hoffmann-Vold, K. Antoniou, J. Avouac, E. Bendstrup, G. Brown, I. Castellví, S. Castaneda, V. Cottin, B. Crestani, P. Dieudé, L. Galvin, J. Jacobs, S. Jones, A. Krause, P. Long, B. Maurer, E. Mosor, T. M. Maher, P. Pchelnikova, N. Tak, J. De Vries-Bouwstra, C. Valenzuela, M. Wijsenbeek, M. Kreuter
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Interstitial lung disease (ILD) can have a significant impact on the long-term outcome in patients with rheumatoid arthritis (RA) but international screening guidelines for early diagnosis of RA-ILD are lacking. It is unknown to date how RA patients are screened for ILD in clinical practice. An analysis of patients' experiences and perspectives will help identify current practice and guide future directions to optimize screening, management and patients care. <h3>Objectives</h3> To identify patients' experiences and unmet clinical needs regarding screening for RA-ILD. <h3>Methods</h3> An international multidisciplinary panel of 18 ILD experts developed and distributed an online-based survey in 12 languages for RA patients with and without ILD from August to December 2022 to receive self-reported data. User representatives of relevant patient associations and RA patients with and without ILD refined and piloted the survey questions. The survey covered management strategies, including information and awareness of ILD, screening for ILD and patient' perspectives on future directions. The study was approved by the Ethics committee of the University Clinic Heidelberg, Germany, and patients consented before starting the online survey. <h3>Results</h3> In total, 1132 RA patients from 11 countries answered the survey. Mean age was 57 (SD13.6) years, 129 (12%) were males, 690 (75%) had seropositive RA with a disease duration of 9.9 (SD7.9) years (Table 1). Of all, 434 (39%) were informed about the possibility of ILD development and 387 (35%) were screened for ILD, of which 75% by x-ray, 49% by high-resolution computed tomography (HRCT), 49% with pulmonary function test (PFT), 23% with respiratory symptoms, 40% with auscultation and 194/387 (59%) were screened with several modalities. Older age, male sex, presence of other lung comorbidities and treatment with Rituximab or Abatacept were associated with screening assessed by multivariable logistic regression (Figure 1). Of all RA patients, 138 (12.4%) were diagnosed with ILD. Screening was significantly associated with an ILD diagnosis (OR 8.87, 95%CI 5.61-14.03, p&lt;0.001) driven by screening for symptoms (OR 1.77 (95% CI 1.06-2.94, p=0.028), PFT (OR 3.42, 95%CI 2.11-5.36, p&lt;0.001) and HRCT (OR 7.17, 95%CI 4.16-12.34, p&lt;0.001). Screening by auscultation or x-ray was not associated with a diagnosis of ILD. Of all RA patients, 89% sought more information about the risk of lung involvement in RA, 95% asked for better information about respiratory symptoms, 71% would prefer that increased attention be paid to potential lung involvement by their treating physician and 98% wanted more research in RA-ILD. <h3>Conclusion</h3> Based on this self-reported patient survey, information about ILD provided to RA patients is frequently limited. Only one third are screened for ILD. The majority of patients stated a clear need for more information on RA-ILD, increasing awareness of lung involvement in RA should be a priority in clinical practice and research. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Anna-Maria Hoffmann-Vold Speakers bureau: Boehringer Ingelheim, Jannsen, Medscape, Merck Sharp &amp; Dohme and Roche, Consultant of: ARXX, Boehringer Ingelheim, Genentech, Jannsen, Medscape, Merck Sharp &amp; Dohme and Roche, Grant/research support from: Boehringer Ingelheim, Jannsen, Katerina Antoniou Speakers bureau: Boehringer Ingelheim, Roche, Consultant of: Boehringer Ingelheim, Roche, Grant/research support from: Boehringer Ingelheim, Jérôme Avouac: None declared, Elisabeth Bendstrup Speakers bureau: Boehringer Ingelheim, Roche, Daichii Sankyo, Graham Brown: None declared, Ivan Castellví: None declared, Santos Castaneda Speakers bureau: BMS, Lilly, Roche, Consultant of: Sanofi, Roche, Vincent Cottin Speakers bureau: Boehringer Ingelheim, Celgene/ BMS, CSL Behring, Roche, Shionogi , Consultant of: Boehringer Ingelheim, Celgene/ BMS, CSL Behring, Ferrer/ United Therapeuticst, Pliant, Pure Tech, RedX, Roche, Shionogi, Grant/research support from: Boehringer Ingelheim: Unrestricted grant to institution, Bruno Crestani Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, Philippe Dieudé: None declared, Liam Galvin: None declared, Joseph Jacobs Speakers bureau: Boehringer Ingelheim, Roche, Takeda, GSK, Consultant of: Boehringer Ingelheim, Roche, Grant/research support from: GSK, Steve Jones: None declared, Andreas Krause Speakers bureau: AbbVie, BMS, Boehringer Ingelheim, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, UCB, Consultant of: AbbVie, BMS, Boehringer Ingelheim, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Grant/research support from: UCB, Preston Long: None declared, Britta Maurer Speakers bureau: Novartis, Boehringer Ingelheim, GSK, MSD, Otsuka, Consultant of: Novartis, Boehringer Ingelheim, Janssen-Cilag, GSK, Grant/research support from: AbbVie, Protagen, Novartis Biomedical, Erika Mosor: None declared, Toby M Maher: None declared, Polina Pchelnikova: None declared, Nelleke Tak Speakers bureau: Boehringer Ingelheim, Grant/research support from: Boehringer Ingelheim, Jeska de Vries-Bouwstra Speakers bureau: Boehringer Ingelheim, Janssen Pharmaceuticals, Consultant of: Abbvie, Boehringer Ingelheim, Grant/research support from: Galapagos, Roche, Boehringer Ingelheim, CLAUDIA VALENZUELA Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, Grant/research support from: Boehringer Ingelheim, Marlies Wijsenbeek Speakers bureau: paid to institution: Boehringer Ingelheim, CSL Behring,Hoffman la Roche, Novartis , Consultant of: paid to institution: Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Galecto, Hoffman la Roche, Horizon therapeutics, Kinevant Sciences, Molecure, Nerre Therapeutics, Novartis, PureTech Health, and Respivant , Grant/research support from: paid to my institution: Boehringer Ingelheim, Astra-Zenca-Daiichi , Michael Kreuter Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, Grant/research support from: Boehringer Ingelheim.